Xenetic Biosciences, Inc.

As of October 1, 2023, there is not enough technical data on Xenetic Biosciences, Inc. to determine if it is bullish or bearish.

As of March 2022, the management team of Xenetic Biosciences, Inc. includes CEO Jeffrey Eisenberg, Treasurer Colin Hill, and Directors Grigory Borisenko, Timothy Cote, Firdaus Dastoor, Artur Isaev, and Roger Kornberg. They oversee the company's strategic direction and operations.

Xenetic Biosciences, Inc. is a biopharmaceutical company specializing in personalized CAR T technology for targeting tumor neoantigens, with a market cap of $4.30 million. As of March 2025, it reported net sales of $1 million and a net loss of $1 million.